Increasingly, the effects of copy number variation (CNV) in the genome on brain function and behaviors are recognized as means to elucidate pathophysiology of psychiatric disorders. Such studies require large samples and we characterized the neurocognitive profile of two cohorts of individuals with 22q11.2 deletion syndrome (22q11DS), the most common CNV associated with schizophrenia, in an effort to harmonize phenotyping in multi-site global collaborations. The Penn Computerized Neurocognitive Battery (PCNB) was administered to individuals with 22q11DS in Philadelphia (PHL; n = 155, aged 12-40) and Tel Aviv (TLV; n = 59, aged 12-36). We examined effect sizes of performance differences between the cohorts and confirmed the factor structure of PCNB performance efficiency in the combined sample based on data from a large comparison community sample. The cohorts performed comparably with notable deficits in executive function, episodic memory and social cognition domains that were previously associated with abnormal neuroimaging findings in 22q11DS. In mixed model analysis, while there was a main effect for site for accuracy (number of correct response) and speed (time to correct response) independently, there were no main site effects for standardized efficiency (average of accuracy and speed). The fit of a structural model was excellent indicating that PCNB tests were related to the targeted cognitive domains. Thus, our results provide preliminary support for the use of the PCNB as an efficient tool for neurocognitive assessment in international 22q11DS collaborations.
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Introduction
There is growing evidence that copy number variation (CNV) in the genome can impact brain function and may underlie some symptoms and cognitive deficits present in neuropsychiatric disorders (Malhotra & Sebat, 2012) . The 22q11.2 deletion syndrome (22q11DS) is a common CNV, affecting approximately 1 in 4000 live births (Botto et al., 2003; Goodship, Cross, LiLing, & Wren, 1998) . A hemizygous deletion of about 60 known genes (Drew et al., 2011) typically occurs de novo during meiotic recombination, mediated by low-copy repeats on the chromosome 22q11.2 region (Edelmann, Pandita, & Morrow, 1999; Shaikh et al., 2000) . This mutation causes extensive phenotypic manifestations. Anomalies including congenital heart defect, thymic and palatal defects,
